Use of inhibitors of bruton's tyrosine kinase (btk)
AssigneePharmacyclics, Inc.
InventorsJoseph J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Claims14
-129. (canceled)
A pharmaceutical composition comprising about 140 mg of a Bruton's tyrosine kinase (BTK) inhibitor compound of Formula (D):
- wherein
- La is CH2, O, NH or S;
- Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl;
- Y is an optionally substituted group selected from among alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- Z is C(═O), OC(═O), NHC(═O), C(═S), S(═O)x, OS(═O)x, NHS(═O)x, where x is 1 or 2;
- R7 and R8 are independently H;
- or
- R7 and R8 taken together form a bond;
- R6 is H,
- and a pharmaceutically-acceptable excipient.
A pharmaceutical composition comprising about 140 mg of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib), and a pharmaceutically-acceptable excipient, formulated into a solid dosage form.
Dependencies are inferred from the claim text.